

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 61

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 61

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 61

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acidum levomefolicum

levomefolic acid

N-(4-[[[(2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino]benzoyl]-L-glutamic acid


acide lévoméfolique

acide *N*-[4-[[[(6*S*)-2-amino-5-méthyl-4-oxo-1,4,5,6,7,8-hexahydroptéridin-6-yl]méthyl]amino]benzoyl]-L-glutamique

ácido levomefólico

ácido *N*-(4-[[[(2-amino-5-metil-4-oxo-3,4,5,6,7,8-hexahidropteridin-6-il)metil]amino]benzoilo]-L-glutámico

C₂₀H₂₅N₇O₆



aderbasibum

aderbasib

methyl (6*S*,7*S*)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate


aderbasib

(6*S*,7*S*)-7-(hydroxycarbamoyl)-6-[(4-phénylpipérazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate de méthyle

aderbasib

(6*S*,7*S*)-6-(4-fenilpiperazina-1-carbonil)-7-(hidroxicarbamoil)-5-azaspiro[2.5]octano-4-carboxilato de metilo

C₂₁H₂₈N₄O₅



adoprazinum

adoprazine


1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine

adoprazine

1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophényl)pyridin-3-yl]méthyl]pipérazine

adoprazina

1-(2,3-dihidro-1,4-benzodioxin-5-il)-4-[[5-(4-fluorofenil)piridin-3-il]metil]piperazina

 $C_{24}H_{24}FN_3O_2$ **alipogenum tiparovecum #**

alipogene tiparovec

recombinant adeno-associated virus serotype 1 (AAV1) vector expressing the S447X variant of the human lipoprotein lipase (LPL) gene

alipogène tiparovec

vecteur adéno-associé virus de type 1 (AAV1) recombinant exprimant le variant S447X du gène humain de la lipoprotéine lipase (demander confirmation de la traduction à MPL et RBD)

alipogén tiparovec

vector viral adeno-asociado recombinante de tipo 1 (AAV1) que expresa la variante S447X del gen humano de lipoproteina lipasa (LPL)

apricoxibum


apricoxib

4-[2-(4-ethoxyphenyl)-4-methyl-1*H*-pyrrol-1-yl]benzenesulfonamide

apricoxib

4-[2-(4-éthoxyphényl)-4-méthyl-1*H*-pyrrol-1-yl]benzènesulfonamide

apricoxib

4-[2-(4-etoxifenil)-4-metil-1*H*-pirrol-1-il]bencenosulfonamida $C_{19}H_{20}N_2O_3S$ 

bafetinibum

bafetinib


N-{3-[[[5,5'-bipyrimidin]-2-yl]amino]-4-methylphenyl}-4-[[[(3*S*)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-3-(trifluoromethyl)benzamide

bafétinib

N-[3-[[[5,5'-bipirimidin]-2-ylamino]-4-méthylphényl]-4-[[[(3*S*)-3-(diméthylamino)pyrrolidin-1-yl]méthyl]-3-(trifluorométhyl)benzamide

bafetinib

N-{3-[[[5,5'-bipirimidin]-2-il]amino]-4-metilfenil}-4-[[[(3*S*)-3-(dimetilamino)pirrolidin-1-il]metil]-3-(trifluorometil)benzamida

C₃₀H₃₁F₃N₈O**bederocinum**

bederocin


2-[[3-[[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methyl]amino]propyl]amino]quinolin-4(1*H*)-one

bédéroceine

2-[[3-[[[4-bromo-5-(1-fluoroéthényl)-3-méthylthiophén-2-yl]méthyl]amino]propyl]amino]quinoléin-4(1*H*)-one

bederocina

2-[[3-[[[4-bromo-5-(1-fluoroetenil)-3-metiltiofen-2-il]metil]amino]propil]amino]quinolin-4(1*H*)-ona

C₂₀H₂₁BrFN₃OS**befiradolum**

befiradol


(3-chloro-4-fluorophenyl)[4-fluoro-4-[[[(5-methylpyridin-2-yl)methyl]amino]methyl]piperidin-1-yl]methanone


béfiradol

(3-chloro-4-fluorophényl)[4-fluoro-4-[[[(5-méthylpyridin-2-yl)méthyl]amino]méthyl]pipéridin-1-yl]méthanone

befiradol

(3-cloro-4-fluorofenil){4-fluoro-4-[[[(5-metilpiridin-2-il)metil]amino]metil]piperidin-1-il}metanona

C₂₀H₂₂ClF₂N₃O




```

SETSRFAFGG RRAVPPNNSN AAEDDLPTVE LQGVVPRGVN LQEFNLVTSV 50
HLFKERWDTN KVDHHTDKYE NNKLIVRRGQ SFYVQIDFSR PYDPRRDLEF 100
VEYVIGRYPQ ENKGTIYPVP IVSELQSGKW GAKIVMREDR SVRLSIQSSP 150
KCIVGKFRMY VAVWTPYGVV RTSRNPETDT YILFNPWCED DAVYLDNEKE 200
REEYVLNDIG VIFYGEVNDI KTRSWSYGQF EDGILDTCCLY VMDRAQMDLS 250
GRGNPIKVSF VGSAMVNAKD DEGVLVGSWD NIYAYGVPPS AWTGSVDILL 300
EYRSSENPVR YGQCWVFAV FNTFLRCLGI PARIVTNYFS AHDNDANLQM 350
DIFLEEDGNV NSKLTKDSVW NYHCWNEAMM TRDPLVGFQ GWQAVDSTPQ 400
ENSDGMYRCG PASVQAIKHG HVCFQFDAPF VFAEVNSDLI YITAKKDGTH 450
VVENVDATHI GKLIIVTKQIG GDGMMDITDT YKFQEQEQUE RLALLETALMY 500
GAKKPLNTEG VMKSRSNVDM DFEVENAVLG KDFKLSITFR NNSHNRYTIT 550
AYLSANITFY TGVPKAEFKK ETFDVTLEPL SFKKEAVLIQ AGEYMGQLLE 600
QASLHFFVTA RINETRDVLA KQKSTVLTIP EIIIKVRGTQ VVGSDMTVTV 650
EFTNPLKETL RNVVHLDGP GVTRPMKKMF REIRPNSTVQ WEEVCRPWVS 700
GHRKLIASMS SDSLRHVYGE LDVQIQRRPS M 731

```

Modified residues / Résidus modifiés / Residuos modificados



citatumabum bogatoxum #
citatumab bogatox

immunoglobulin Fab fusion protein, anti-[*Homo sapiens* tumor-associated calcium signal transducer 1 (TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, CD326)], humanized Fab fused with *Bougainvillea spectabilis* Willd rRNA N-glycosidase [type I ribosome inactivating protein (RIP), bouganin], VB6-845; gamma1 heavy chain fragment (1-225) [hexahistidyl (1-6) -humanized VH from 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01, V124>L) [8.8.9] (7-122) -*Homo sapiens* IGHG1*01 CH1-hinge fragment EPKSC (123-225)], (225-219')-disulfide with kappa fusion chain (1'-481') [humanized V-KAPPA from clone 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ1*01, I126>L) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219') -12-mer furin linker (proteolytic cleavage spacer from *Pseudomonas* exotoxin A) (220'-231') -*Bougainvillea spectabilis* Willd bouganin fragment (27-276 from precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

citatumab bogatox

immunoglobuline Fab protéine de fusion, anti-[*Homo sapiens* transducteur 1 du signal calcium associé aux tumeurs (TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, molécule d'adhésion de la cellule épithéliale Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, CD326)], humanisé Fab fusionné avec la N-glycosidase de l'ARNr [protéine de type I inactivant le ribosome (RIP), bouganine] de *Bougainvillea spectabilis* Willd, VB6-845; fragment de chaîne lourde gamma1 (1-225) [hexahistidyl (1-6) -VH humanisé de 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01, V124>L) [8.8.9] (7-122) -*Homo sapiens* IGHG1*01 CH1-fragment de la charnière EPKSC (123-225)], (225-219')-disulfure avec la chaîne kappa de fusion (1'-481') [V-KAPPA humanisé du clone 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ1*01, I126>L) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219') -12-mer furin linker (motif de clivage protéolytique de *Pseudomonas* exotoxin A) (220'-231') -*Bougainvillea spectabilis* Willd bouganine fragment (27-276 du précurseur, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

citatumumab bogatox

inmunoglobulina Fab proteína de fusión, anti-[*Homo sapiens* transductor 1 de la señal de calcio asociado a tumores (TACSTD1, proteína 2 asociada a tumores gastrointestinales, GA733-2, glicoproteína epitelial 2, EGP-2, molécula de adhesión de la célula epitelial Ep-CAM, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, CD326)], humanizado Fab fusionado con la N-glicosidasa de ARNr [proteína de tipo I inactivadora del ribosoma (RIP)] de *Bougainvillea spectabilis Willd*, VB6-845; fragmento de cadena pesada gamma1 (1-225) [hexahistidil (1-6) -VH humanizado de 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01, V124>L) [8.8.9] (7-122) -*Homo sapiens* IGHG1*01 CH1-fragmento de la bisagra EPKSC (123-225)], (225-219')-disulfuro con la cadena kappa de fusión (1'-481') [V-KAPPA humanizado del clon 4D5MOC-B (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ1*01, I126>L) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219') -12-mer ligante de furina (espaciador de ruptura proteolítica de *Pseudomonas* exotoxin A) (220'-231') – buganina de *Bougainvillea spectabilis Willd* fragmento (27-276 del precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]

C₃₄₅₅H₅₃₇₁N₉₂₁O₁₀₆₀S₁₈

Heavy chain / Chaîne lourde / Cadena pesada

HHHHHHEVQL	VQSGPGLVQP	GGSVRISCAA	SGYTFTNYGM	NWVKQAPGKG	50
LEWMGWINTY	TGESTYADSF	KGRFTFSLDT	SASAAYLQIN	SLRAEDTAVY	100
YCARFAIKGD	YWGQGTLLTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	200
QTYICNVNHK	PSNTKVDKKV	EPKSC			225

Light chain-toxin / Chaîne légère-toxine / Cadena ligera-toxina

DIQMTQSPSS	LSASVGDRTV	ITCRSTKSL	HSNGITYLYW	YQKPKGKAPK	50'
LLIYQMSNLA	SGVPSRFSS	SGGTFDLTI	SSLQPEDFAT	YYCAQNLLEIP	100'
RTPGQGTQVE	LKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKDYSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGECT	RHRQPRGWEQ	LYNTVSNFLG	EAYEYPTFFIQ	250'
DLRNELAKGT	PVCQLPVTLQ	TIADDKRFVL	VDITTTSKKT	VKVAIDVTDV	300'
YVVGYYQDKWD	GKDRAVFLDK	VPTVATSKLF	PGVTNRVTLT	FDGSYQKLVN	350'
AAKADRKALE	LGVNKLFSI	EAIHGKTING	QEAAKFFFLIV	IQMVSEAAARF	400'
KYIETEYVDR	GLYGSFKPNF	KVLNLENNWG	DISDAIHKSS	PQCTTINPAL	450'
QLISPSNDPW	VVNKVSQISP	DMGILKFKSS	K		481'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
23'-93' 28-102 139'-199' 149-205 219'-225 263'-443'

conatumumabum #
conatumumab

immunoglobulin G1, anti-[*Homo sapiens* tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, TR-2, CD262)], *Homo sapiens* monoclonal antibody, XG1-048 v w (or AMG 655, TRAIL-R2mAb); gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) - IGHG1*03 (123-452)], (225-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (231-231":234-234")-bisdisulfide dimer

conatumumab	<p>immunoglobuline G1, anti-[<i>Homo sapiens</i> membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale (TNFRSF10B, death receptor 5, DR5, TRAIL-R2, TR-2, CD262)], <i>Homo sapiens</i> anticorps monoclonal, XG1-048 v w (ou AMG 655, TRAIL-R2mAb); chaîne lourde gamma1 (1-452) [<i>Homo sapiens</i> VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215') [<i>Homo sapiens</i> V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (231-231":234-234")-bisdisulfure</p>
conatumumab	<p>inmunoglobulina G1, anti-[<i>Homo sapiens</i> miembro 10B de la superfamilia de receptores del factor de necrosis tumoral (TNFRSF10B, receptor mortal 5, DR5, TRAIL-R2, TR-2, CD262)], <i>Homo sapiens</i> anticorps monoclonal, XG1-048 v w (o AMG 655, TRAIL-R2mAb); cadena pesada gamma1 (1-452) [<i>Homo sapiens</i> VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123-452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215') [<i>Homo sapiens</i> V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (231-231":234-234")-bisdisulfuro</p> <p>C₆₄₆₆H₁₀₀₀₆N₁₇₃₀O₂₀₂₄S₄₀</p> <p>Heavy γ1-chain / Chaîne lourde γ1 / Cadena pesada γ1</p> <p>QVQLQESGPG LVKPSQTLST TCTVSGGSIS SGDYFWSWIR QLPKGLEWLI 50 GHIHNSGTTY YNPSLKSRTV ISVDTSKKQF SLRLSSVTAA DTAVYYCARD 100 RGGDYYYGMD VNGQGTTVTV SSASTKGPSV FPLAPSSKST SGTAAALGCL 150 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTFPSSSLGT 200 QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSTVFLFPP 250 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300 YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTTP 400 PVLDSDSGSEF LYSKLTVDKS RWQQGNVFPSC SVMHEALHNN YTKQSLSLSP 450 GK 452</p> <p>Light κ-chain / Chaîne légère κ / Cadena ligera κ</p> <p>EIVLTQSPGT LSLSPGERAT LSCRASQGIS RSYLAWYQQK PGQAPSLLIY 50' GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QFGSSPWTFG 100' QGTYKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNE YPREAKVQWK 150' VDNALQSGNS QESVTEQDSK DSTYLSLSTL TLSKADYEKH KYVACEVTHQ 200' GLSSPVTKSF NRGEK 215'</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>22-97 22"-97" 23"-89" 23"-89" 135"-195" 135"-195" 149-205 149"-205" 215'-225 215"-225" 231-231" 234-234" 266-326 266"-326" 372-430 372"-430"</p> <p>Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación</p> <p>N = Asn-302 Asn-302"</p>
custirsenum custirsen	<p>2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioguanlylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-deoxy-<i>P</i>-thioguanlylyl-(3'→5')-2'-deoxy-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-deoxy-<i>P</i>-thioguanlylyl-(3'→5')-2'-deoxy-(3'→5')-2'-deoxy-<i>P</i>-thioguanlylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-deoxy-<i>P</i>-thioguanlylyl-(3'→5')-<i>P</i>-thiothymidylyl-(3'→5')-2'-deoxy-<i>P</i>-thiocytidylyl-(3'→5')-<i>P</i>-thiothymidylyl-(3'→5')-2'-deoxy-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine</p>

custirsén
 2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-*P*-thioguanilyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanilyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanilyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanilyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridine

custirsén
 2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-*P*-thioguanilyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridine

$C_{231}H_{312}N_{78}O_{119}P_{20}S_{20}$

(3' 5')d(P-thio)(rC-rA-rG-rC-A-G-C-A-G-A-G-T-C-T-T-C-A-rU-rC-rA-rU)
 Modified nucleosides
 A = 2'-O-(2-méthoxyéthyl)adenosine
 C = 2'-O-(2-méthoxyéthyl)-5-méthylcytidine
 G = 2'-O-(2-méthoxyéthyl)guanosine
 U = 2'-O-(2-méthoxyéthyl)-5-méthyluridine


danusertibum

danusertib
 N-{5-[(2*R*)-2-méthoxy-2-phénylacétyl]-1,4,5,6-tétrahydropyrrolo[3,4-*c*]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl)benzamide

danusertib
 N-{5-[(2*R*)-2-méthoxy-2-phénylacétyl]-1,4,5,6-tétrahydropyrrolo[3,4-*c*]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl)benzamide

danusertib
 N-{5-[(2*R*)-2-fenil-2-metoxiacetil]-1,4,5,6-tétrahidropirrollo[3,4-*c*]pirazol-3-il}-4-(4-metilpipérazin-1-il)benzamida

$C_{26}H_{30}N_6O_3$



darotropii bromidum


darotropium bromide

(1*R*,3*r*,5*S*)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide

bromure de darotropium

bromure de (1*R*,3*r*,5*S*)-3-(2-cyano-2,2-diphényléthyl)-8,8-diméthyl-8-azabicyclo[3.2.1]octan-8-ium

bromuro de darotropio

bromuro de (1*R*,3*r*,5*S*)-3-(2-ciano-2,2-difeniletíl)-8,8-dimetil-8-azabicio[3.2.1]octan-8-ioC₂₄H₂₉BrN₂**demiditrazum**


demiditraz

2-[(1*S*)-1-(2,3-dimethylphenyl)ethyl]-1*H*-imidazole

démiditraz

2-[(1*S*)-1-(2,3-diméthylphényl)éthyl]-1*H*-imidazole

demiditraz

2-[(1*S*)-1-(2,3-dimetilfenil)etil]-1*H*-imidazolC₁₃H₁₆N₂**denenicokinum**

denenicokin

recombinant L-methionyl(human interleukin-21) (134 amino acids), produced in *Escherichia coli*

dénénicokine

L-méthionyl(interleukine-21 humaine), recombinante (134 acides aminés), produite par *Escherichia coli*

denenicokina

L-metionil(interleukina-21 humana), recombinante (134 aminoácido), producida por *Escherichia coli*C₆₇₆H₁₀₈₇N₂₀₅O₂₀₃S₈

QGQDRHMIRM	RQLIDIVDQL	KNYVNDLVE	FLPAPEDVET	NCEWSAFSCF	50
QKAQLKSANT	GNNERIINVS	IKKLRKPPPS	TNAGRRQKHR	LTCPSCDSYE	100
KKPPKEFLER	FKSLQKMIH	QHLSSRTHGS	EDS		133

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
42-93 49-96**derquantelum**


derquantel

(1'*R*,5*a*'*S*,7'*R*,8*a*'*S*,9*a*'*R*)-1'-hydroxy-1',4,4,8',11'-hexamethyl-2',3',8*a*',9,9',10-hexahydro-4*H*,1'*H*,5'*H*,6'*H*,8'*H*-spiro[[1,4]dioxepino[2,3-*g*]indole-8,7'-[5*a*,9*a*](epiminomethano)cyclopenta[*f*]indolizin]-10'-one

derquantel (1'R,5'aS,7'R,8'aS,9'aR)-1'-hydroxy-1',4,4,8',8',11'-hexaméthyl-2',3',8'a,9,9',10-hexahydro-1'H,4H,5'H,6'H,8'H-spiro[[1,4]dioxépine[2,3-g]indole-8,7'-[5a,9a](épiminométhano)cyclopenta[*f*]indolizin]-10'-one

derquantel (1'R,5'aS,7'R,8'aS,9'aR)-1'-hidroxi-1',4,4,8',8',11'-hexametil-2',3',8'a,9,9',10-hexahidro-4H,1'H,5'H,6'H,8'H-espiro[[1,4]dioxepino[2,3-g]indol-8,7'-[5a,9a](epiminometano)ciclopenta[*f*]indolizin]-10'-ona

C₂₈H₃₇N₃O₄



disitertidum
disitertide

human Transforming Growth Factor-beta receptor type III-(710-723)-peptide

disitertide

récepteur de type III du facteur de croissance transformant-bêta humain-(710-723)-peptide

disitertida

receptor de tipo III del factor de crecimiento transformador-beta humano-(710-723)-péptido

C₆₈H₁₀₉N₁₇O₂₂S₂

H-Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn-OH
10 14

drinabantum
drinabant

N-{1-[bis(4-chlorophenyl)methyl]azetidín-3-yl}-N-(3,5-difluorophenyl)methanesulfonamide


drinabant

N-{1-[bis(4-chlorophényl)méthyl]azétidín-3-yl}-N-(3,5-difluorophényl)méthanesulfonamide

drinabant

N-{1-[bis(4-clorofenil)metil]azetidín-3-il}-N-(3,5-difluorofenil)metanosulfonamida

C₂₃H₂₀Cl₂F₂N₂O₂S



dulanerminum

dulanermin

human tumor necrosis factor ligand superfamily member 10 (TNF-related apoptosis-inducing ligand or Apo-2 ligand or CD253 antigen)-(114-281)-peptide (C-terminal part of the extracellular domain), noncovalent homotrimer

dulanermine

membre 10 de la superfamille de ligand du facteur de nécrose tumorale humaine (ligand inducteur d'apoptose apparenté au TNF ou Apo-2 ligand ou antigène CD253)-(114-281)-peptide (extrémité -terminale du domaine extracellulaire), homotrimer nonacovalent

dulanermina

miembro 10 de la superfamilia de ligandos del factor de necrosis tumoral humano (ligando inductor de apoptosis relacionada con el TNF o Apo-2 ligand o antígeno CD253)-(114-281)-péptido (extremo C-terminal del dominio extracelular), homotrímero nonacovalente

C₈₇₁H₁₃₂₉N₂₄₃O₂₆₀S₄

Monomer

VRERGPQRVA	AHITGTRGRS	NTLSSPNSKN	EKALGRKINS	WESSRSRGSF	50
LSNLHLRNGE	LVIHEKGFYY	IYSQTYFRFQ	EIKENTKND	KQMVQYIYKY	100
TSYDPDILLM	KSARNSCWSK	DAEYGLYSIY	QGGIFELKEN	DRIFVSVTNE	150
HLIDMDHEAS	FFGAFLVG				168

edoxabanum

edoxaban


N-(5-chloropyridin-2-yl)-*N*'-[(1*S*,2*R*,4*S*)-4-(*N,N*-dimethylcarbamoyl)-2-(5-méthyl-4,5,6,7-tétrahydro[1,3]thiazolo[5,4-*c*]pyridine-2-carboxamido)cyclohexyl]oxamide

édoxaban

N-(5-chloropyridin-2-yl)-*N*'-[(1*S*,2*R*,4*S*)-4-(*N,N*-diméthylcarbamoyl)-2-(5-méthyl-4,5,6,7-tétrahydro[1,3]thiazolo[5,4-*c*]pyridine-2-carboxamido)cyclohexyl]oxamide

edoxabán

N-(5-cloropiridin-2-il)-*N*'-[(1*S*,2*R*,4*S*)-4-(*N,N*-dimetilcarbamoi)-2-(5-metil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-*c*]piridina-2-carboxamido)ciclohexil]oxamida

C₂₄H₃₀ClN₇O₄S**elagolixum**


elagolix

4-((1*R*)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluorométhyl)phenyl]méthyl]-4-méthyl-2,6-dioxo-3,6-dihydropyrimidin-1(2*H*)-yl]-1-phenylethyl)amino)butanoic acid

élagolix acide 4-(((1*R*)-2-[5-(2-fluoro-3-méthoxyphényl)-3-[[2-fluoro-6-(trifluorométhyl)phényl]méthyl]-4-méthyl-2,6-dioxo-3,6-dihydropyrimidin-1(2*H*)-yl]-1-phényléthyl)amino)butanoïque

elagolix ácido 4-(((1*R*)-2-[5-(2-fluoro-3-metoxifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-4-metil-2,6-dioxo-3,6-dihidropirimidin-1(2*H*)-il]-1-feniletíl)amino)butanoico

$C_{32}H_{30}F_5N_3O_5$




elesclomolum

elesclomol *N,N'*-diméthyl-*N,N'*-di(benzenecarbonothioyl)propanedihydrazide

élesclomol 1-*N'*,3-*N'*-diméthyl-1-*N'*,3-*N'*-dibenzèncarbonothioylpropanedihydrazide

elesclomol *N,N'*-dimetil-*N,N'*-di(bencenocarbonotioil)propanodihidrazida

$C_{19}H_{20}N_4O_2S_2$




entinostatam

entinostat (pyridin-3-yl)méthyl ({4-[(2-aminophényl)carbamoyl]phényl}méthyl)carbamate

entinostat ({4-[(2-aminophényl)carbamoyl]phényl}méthyl)carbamate de pyridin-3-ylméthyle

entinostat ({4-[(2-aminofenil)carbamoil]fenil}metil)carbamato de (piridin-3-il)metilo

$C_{21}H_{20}N_4O_3$



eprotiromum

eprotrirome


3-({3,5-dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}amino)-3-oxopropanoic acid

éprotrirome

acide 3-({3,5-dibromo-4-[4-hydroxy-3-(1-méthyléthyl)phénoxy]phényl}amino)-3-oxopropanoïque

eprotriromo

ácido 3-({3,5-dibromo-4-[4-hidroxi-3-(propan-2-il)fenoxi]fenil}amino)-3-oxopropanoico

C₁₈H₁₇Br₂NO₅**esreboxetinum**

esreboxétine


(2S)-2-[(2-ethoxyphenoxy)(phenyl)methyl]morpholine

esréboxétine

(+)-(2S)-2-[(S)-(2-éthoxyphénoxy)phénylméthyl]morpholine

esreboxetina

(2S)-2-[(2-etoxifenoxi)(fenil)metil]morfolina

C₁₉H₂₃NO₃**etaracizumabum #**

etaracizumab

immunoglobulin G1, anti-[*Homo sapiens* alphaVbeta3 integrin (CD51/CD61, CD51/GPIIIa, CD51/platelet membrane glycoprotein IIIa, vitronectin receptor)], humanized monoclonal antibody, MEDI-522 (or hLM609); gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR from clone LM609-*Homo sapiens* IGHJ5*01, L123>T) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR from clone LM609-*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (226-226":230-230")-bisdisulfide dimer

étaracizumab

immunoglobuline G1, anti-[*Homo sapiens* alphaVbeta3 intégrine (CD51/CD61, CD51/GPIIIa, CD51/glycoprotéine membranaire IIIa des plaquettes, récepteur de la vitronectine)], anticorps monoclonal humanisé, MEDI-522 (ou hLM609); chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR du clone LM609-*Homo sapiens* IGHJ5*01, L123>T) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR du clone LM609-*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (226-226":230-230")-bisdisulfure

etaracizumab

inmunoglobulina G1, anti-[*Homo sapiens* alfaVbeta3 integrina (CD51/CD61, CD51/GPIIIa, CD51/glicoproteína IIIa de membrana de plaquetas, receptor de la vitronectina)], anticuerpo monoclonal humanizado, MEDI-522 (o hLM609); cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR del clon LM609-*Homo sapiens* IGHJ5*01, L123>T) [8.8.10] (1-117) - *Homo sapiens* IGHG1*03 (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* FR/*Mus musculus* CDR del clon LM609-*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (226-226":230-230")-bisdisulfuro

C₆₃₉₂H₉₉₀₈N₁₇₃₂O₁₉₉₆S₄₂

γ-Heavy chain/ Chaîne γ lourde/ Cadena γ pesada

QVQLVESGGG	VVQPGKSLRL	SCAASGFTFS	SYDMSWVRQA	PGKGLEWVAK	50
VSSGGGSTYY	LDTVQGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARHL	100
HGSFASWGQG	TTVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	SSLGTQTYIC	200
NVNHKPSNTK	VDKRVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTTPPVLDS	400
DGSFFLYSKL	TVDKSRWQQG	NVFSCSVME	ALHNHYTQKS	LSLSPGK	447

κ-Light chain/ Chaîne κ légère/ Cadena κ ligera

EIVLTQSPAT	LSLSPGERAT	LSCQASQGIS	NFLHWYQRRP	GQAPRLLRIR	50'
RSQISIGIPA	RFGSGSGTD	FTLTISLEP	EDFAVYYCQQ	SGSWPLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96	22"-96"	23'-88'	23""-88""	134'-194'	134""-194""	144-200	144"-200"
214'-220	214""-220"	226-226"	229-229"	261-321	261"-321"	367-425	367"-425"

foravirumabum #
foravirumab

immunoglobulin G1-kappa, anti-[rabies virus glycoprotein], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

foravirumab

immunoglobuline G1-kappa, anti-[glycoprotéine du virus de la rage], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

foravirumab

inmunoglobulina G1-kappa, anti-[glicoproteína del virus de la rabia], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

C₆₄₀₀H₉₉₁₄N₁₇₁₈O₁₉₉₈S₄₄

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG AVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50
 ILYDGSDFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVA 100
 VAGTHFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
 YFPEPVTYSW NSGALTVGVH TFPVQLQSSG LYSLSVVTV PSSSLGTQTY 200
 ICNVNHKPSN TKVDKRVEPK SCDKTHTCP CPAPPELLGGP SVFLFPPKPK 250
 DTLMISRPE VTCVVDVSH EDEVKFNWY VDGVEVHNAK TKPREEQNS 300
 TYRVVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
 YTLPPSREEM TRNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPEVL 400
 DSDGSEFLLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVIT ITCRASQGIT NDLGWYQQK GKAPKLLIYA 50
 ASSLQSGVPS RFSGSGSGTD FTLTISLQPE EDFATYVCQQ LNSYPPTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQKVK 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427
 22"-96" 146"-202" 263"-323" 369"-427"
 Intra-L 23"-88" 134"-194"
 23"-88" 134"-194"
 Inter-H-L 222-214' 222"-214"
 Inter-H-H 228-228" 231-231"

N-glycosylation sites / Sites de *N*-glycosylation / Posiciones de *N*-glicosilación
 299, 299"

ibipinabantum

ibipinabant


(*E*,4*S*)-*N'*-(4-chlorobenzenesulfonyl)-3-(4-chlorophenyl)-*N*-methyl-4-phenyl-4,5-dihydro-1*H*-pyrazole-1-carboximidamide

ibipinabant

(*E*,4*S*)-*N'*-(4-chlorobenzènesulfonyl)-3-(4-chlorophényl)-*N*-méthyl-4-phényl-4,5-dihydro-1*H*-pyrazole-1-carboximidamide

ibipinabant

(*E*,4*S*)-*N'*-(4-clorobenzenosulfonyl)-3-(4-clorofenil)-4-fenil-*N*-metil-4,5-dihidro-1*H*-pirazol-1-carboximidamida

C₂₃H₂₀Cl₂N₄O₂S

intiquinatum


intiquinate

(2*R*)-2-{4-[(7-bromoquinolin-2-yl)oxy]phenoxy}propanoic acid

intiquinate

acide (2*R*)-2-{4-[(7-bromoquinoléin-2-yl)oxy]phénoxy}propanoïque

intiquinata

ácido (2*R*)-2-{4-[(7-bromoquinolin-2-il)oxi]fenoxi}propanoicoC₁₈H₁₄BrNO₄**lancovutidum**


lancovutide

(C^{3,15}*R*)-C^{3,15}-hydroxy[2-L-lysine, 10-L-phenylalanine, 12-L-phenylalanine-, 13-L-valine]antibiotic ancovenin (*Streptomyces* sp)

lancovutide

(C^{3,15}*R*)-C^{3,15}-hydroxy[2-L-lysine, 10-L-phénylalanine, 12-L-phénylalanine-, 13-L-valine]ancovénine antibiotique (*Streptomyces* sp)

lancovutida

C^{3,15}*R*)-C^{3,15}-hidroxi[2-L-lisina, 10-L-fenilalanina, 12-L-fenilalanina-, 13-L-valina]ancovenina antibiótico (*Streptomyces* sp)C₈₉H₁₂₅N₂₃O₂₅S₃**larazotidum**

larazotide

glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyll-L-prolylglycine

larazotide

glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyll-L-prolylglycine

larazotida

glicilglicil-L-valil-L-leucil-L-valil-L-glutaminil-L-proliilglicina

C₃₂H₅₅N₉O₁₀

H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH

lensiprazinum

lensiprazine


(2*R*)-8-{4-[3-(5-fluoro-1*H*-indol-3-yl)propyl]piperidin-1-yl}-2-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one

lensiprazine

(-)-(2*R*)-8-{4-[3-(5-fluoro-1*H*-indol-3-yl)propyl]pipérazin-1-yl}-2-méthyl-2*H*-1,4-benzoxazin-3(4*H*)-one

lensiprazina

(2*R*)-8-{4-[3-(5-fluoro-1*H*-indol-3-il)propil]piperidin-1-il}-2-metil-2*H*-1,4-benzooxazin-3(4*H*)-ona

C₂₄H₂₇FN₄O₂**levomilnacipranum**


levomilnacipran

(1*S*,2*R*)-2-(aminométhyl)-*N,N*-diéthyl-1-phénylcyclopropanecarboxamide

lévomilnacipran

(-)-(1*S*,2*R*)-2-(aminométhyl)-*N,N*-diéthyl-1-phénylcyclopropanecarboxamide

levomilnaciprán

(-)-(1*S*,2*R*)-2-(aminometil)-*N,N*-dietil-1-fenilcyclopropanecarboxamidaC₁₅H₂₂N₂O**linagliptinum**


linagliptin

8-[(3*R*)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-méthyl-1-[(4-méthylquinazolin-2-yl)méthyl]-3,7-dihydro-1*H*-purine-2,6-dione

linagliptine

8-[(3*R*)-3-aminopéridin-1-yl]-7-(but-2-yn-1-yl)-3-méthyl-1-[(4-méthylquinazolin-2-yl)méthyl]-3,7-dihydro-1*H*-purine-2,6-dione

linagliptina

8-[(3*R*)-3-aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil-1-[(4-metilquinazolin-2-il)metil]-3,7-dihidro-1*H*-purina-2,6-dionaC₂₅H₂₈N₈O₂**lixisenatidum**

lixisenatide


des-38-proline-exendine-4 (*Heloderma suspectum*)-(1-39)-peptidylpenta-L-lysyl-L-lysineamide

lixisénatide

dés-38-proline-exendine-4 (*Heloderma suspectum*)-(1-39)-peptidylpenta-L-lysyl-L-lysineamide

lixisenatida

des-38-prolina-exendina-4 (*Heloderma suspectum*)-(1-39)-peptidilpenta-L-lisil-L-lisineamida



H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-
 10
 Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-
 20
 Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-
 30 40
 Lys-Lys-NH₂
 44

macitentanum

macitentan



N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]ethoxy}pyrimidin-4-yl]-*N'*-propylsulfuric diamide

macitentan

N-[5-(4-bromophényl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]éthoxy}pyrimidin-4-yl]-*N'*-propyldiamide sulfurique

macitentan

N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]etoxi}pirimidin-4-il]-*N'*-propildiamida sulfúrica

**melogliptinum**

melogliptin



(2*S*,4*S*)-4-fluoro-1-[2-({(1*R*,3*S*)-3-[(1*H*-1,2,4-triazol-1-yl)methyl]cyclopentyl)amino)acetyl]pyrrolidine-2-carbonitrile

méglioptine

(2*S*,4*S*)-4-fluoro-1-[2-({(1*R*,3*S*)-3-[(1*H*-1,2,4-triazol-1-yl)méthyl]cyclopentyl)amino)acétyl]pyrrolidine-2-carbonitrile

melogliptina

(2*S*,4*S*)-4-fluoro-1-[2-({(1*R*,3*S*)-3-[(1*H*-1,2,4-triazol-1-il)metil]ciclopentil)amino)acetil]pirrolidina-2-carbonitrilo



mimopezilum


mimopezil

(5*R*,9*R*)-5-[[[(5-chloro-2-hydroxy-3-methoxyphenyl)methylidene]amino]-11-[(*E*)-ethylidene]-7-methyl-5,6,9,10-tetrahydro-5,9-methanocycloocta[*b*]pyridin-2(1*H*)-one

mimopézil

(5*R*,9*R*)-5-[[[(5-chloro-2-hydroxy-3-méthoxyphényl)méthylidène]amino]-11-[(*E*)-éthylidène]-7-méthyl-5,6,9,10-tétrahydro-5,9-méthanocycloocta[*b*]pyridin-2(1*H*)-one

mimopezilo

(5*R*,9*R*)-5-[[[(5-cloro-2-hidroxi-3-metoxifenil)metilideno]amino]-11-[(*E*)-etilideno]-7-metil-5,6,9,10-tetrahidro-5,9-metanocicloocta[*b*]piridin-2(1*H*)-onaC₂₃H₂₃ClN₂O₃**mipomersenum**

mipomersen

antisense oligonucleotide inhibitor of apolipoprotein B (APOB) expression

2'-*O*-(2-methoxyethyl)-*P*-thioguanlyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanlyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanlyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanlyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidine

mipomersen

oligonucléotide antisens, inhibiteur de l'expression de l'apolipoprotéine B (APOB)

2'-*O*-(2-méthoxyéthyl)-*P*-thioguanlyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanlyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanlyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidine


mipomersén

oligonucleótido antisentido inhibidor de la expresión de la apolipoproteína B (APOB)

2'-O-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metilcitidina

C₂₃₀H₃₂₄N₆₇O₁₂₂P₁₉S₁₉(3'-5')(P-thio)(G-C-C-U-C-dA-dG-dT-dC-dT-dG-dT-dT-dC-G-C-A-C-C)

Modified nucleosides / Nucléosides modifiés / Nucleósidos modificados

**niraxostatam**


niraxostat

1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1*H*-pyrazole-4-carboxylic acid

niraxostat

acide 1-[3-cyano-4-(2,2-diméthylpropoxy)phényl]-1*H*-pyrazole-4-carboxylique

niraxostat

ácido 1-[3-ciano-4-(2,2-dimetilpropoxi)fenil]-1*H*-pirazol-4-carboxílicoC₁₆H₁₇N₃O₃

olesoximum


olesoxime

(EZ)-*N*-(cholest-4-en-3-ylidene)hydroxylamine

olésoxime

(EZ)-*N*-(cholest-4-én-3-ylidène)hydroxylamine

olesoxima

(EZ)-*N*-(colest-4-en-3-ilideno)hidroxilaminaC₂₇H₄₅NO**ombrabulinum**


ombrabulin

(2*S*)-2-amino-3-hydroxy-*N*-(2-methoxy-5-[(1*Z*)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl)propanamide

ombrabuline

(2*S*)-2-amino-3-hydroxy-*N*-(2-méthoxy-5-[(1*Z*)-2-(3,4,5-triméthoxyphényl)éthényl]phényl)propanamide

ombrabulina

(2*S*)-2-amino-3-hidroxi-*N*-(2-metoxi-5-[(1*Z*)-2-(3,4,5-trimetoxifenil)etenil]fenil)propanamidaC₂₁H₂₆N₂O₆**otenabantum**


otenabant

1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9*H*-purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide

oténabant

1-[8-(2-clorofenil)-9-(4-clorofenil)-9*H*-purin-6-yl]-4-(étylamino)piperidina-4-carboxamida

otenabant

1-[8-(2-clorofenil)-9-(4-clorofenil)-9*H*-purin-6-il]-4-(etilamino)piperidina-4-carboxamidaC₂₅H₂₅Cl₂N₇O

palifosfamidum


palifosfamide

N,N'-bis(2-chloroethyl)phosphorodiamidic acid

palifosfamide

acide *N,N'*-bis(2-chloroéthyl)phosphorodiamidique

palifosfamida

ácido *N,N'*-bis(2-cloroetil)fosforodiamídicoC₄H₁₁Cl₂N₂O₂P**palovarotenum**


palovarotene

4-[(1*E*)-2-{5,5,8,8-tetramethyl-3-[(1*H*-pyrazol-1-yl)methyl]-5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl]benzoic acid

palovarotène

acide 4-[(1*E*)-2-{5,5,8,8-tétraméthyl-3-(1*H*-pyrazol-1-yl)méthyl}-5,6,7,8-tétrahydronaphtalén-2-yl]éthényl]benzoïque

palovaroteno

ácido 4-[(1*E*)-2-{5,5,8,8-tetrametil-3-[(1*H*-pirazol-1-il)metil]-5,6,7,8-tetrahidronaftalen-2-il}etenil]benzoicoC₂₇H₃₀N₂O₂**radezolidum**


radezolid

N-{[(5*S*)-3-(2-fluoro-4'-{[(1*H*-1,2,3-triazol-4-yl)methyl]amino)methyl}[1,1'-biphenyl]-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide

radézolid

N-{[(5*S*)-3-(2-fluoro-4'-{[(1*H*-1,2,3-triazol-4-yl)méthyl]amino)méthyl}biphényl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]méthyl}acétamide

radezolid

N-{[(5*S*)-3-(2-fluoro-4'-{[(1*H*-1,2,3-triazol-4-il)metil]amino)metil}[1,1'-bifenil]-4-il)-2-oxo-1,3-oxazolidin-5-il]metil}acetamidaC₂₂H₂₃FN₆O₃

rafivirumabum #

rafivirumab	immunoglobulin G1-lambda, anti-[rabies virus glycoprotein], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-456) [<i>Homo sapiens</i> VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfide with lambda light chain (1'-218') [<i>Homo sapiens</i> V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; (236-236":239-239")-bisdisulfide dimer
rafivirumab	immunoglobuline G1-lambda, anti-[glycoprotéine du virus de la rage], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfure avec la chaîne légère lambda (1'-218') [<i>Homo sapiens</i> V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dimère (236-236":239-239")-bisdisulfure
rafivirumab	inmunoglobulina G1-lambda, anti-[glicoproteína del virus de la rabia], <i>Homo sapiens</i> anticuerpo monoclonal; cadena pesada gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfuro con la cadena ligera lambda (1'-218') [<i>Homo sapiens</i> V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dímero (236-236":239-239")-bisdisulfuro

C₆₄₆₂H₉₉₅₄N₁₇₁₈O₂₀₃₆S₄₆

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGSSVKV SCKASGGTFN RYTVNWVRQA PGQGLEWMGG 50
IIPFGTANY AQRFGRLTI TADESTSTAY MELSSLRSDD TAVYFCAREN 100
LDNSGTYIYF SGWFDPWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVP 200
SSLGTTQYIC NVNHKFSNTK VDKRVEPKSC DKHTTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIISKAK 350
GQPREPQVYI LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTTPPVLD DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNYTQKS 450
LSLSPG 456

```

Light chain / Chaîne légère / Cadena ligera

```

QSALTQPRSV SGSPGQSVTI SCTGTSSDIG GYNFVSWYQQ HPGKAPKLM 50
YDATKRPSTV PDRFSGSKSG NTASLTISGL QAEDEADYIC CSYAGDYTPG 100
VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150
TVAWKADSSP VKAGVETTP SKQSNNKYAA SSYLSLTPEQ WKSRSYSYSC 200
VTHEGSTVEK TVAPTECS 218

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 154-210 277-331 377-435
        22"-96" 154"-210" 277"-331" 377"-435"
Intra-L 22'-90' 140"-199"
        22"-90" 140"-199"
Inter-H-L 230-217' 230"-217"
Inter-H-H 236-236" 239-239"

```

N-glycosylation sites / Sites de *N*-glycosylation / Posiciones de *N*-glicosilación
307, 307"

retaspimycinum

retaspimycin


(4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21)4,6,10,18(22),19-hexaen-9-yl carbamate

rétaspimicine

carbamate de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13,20,22-trihydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3-oxo-19-(prop-2-énylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexén-9-yle

retaspimicina

carbamato de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13,20,22-trihidroxi-4,10,12,16-tetrametil-8,14-dimetoxi-3-oxo-19-[(prop-2-en-1-il)amino]-2-azabicyclo[16.3.1]docasa-1(21)4,6,10,18(22),19-hexaen-9-ilo

C₃₁H₄₅N₃O₈**saracatinibum**

saracatinib


N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yl)oxy]quinazolin-4-amine

saracatinib

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-méthylpipérazin-1-yl)éthoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine

saracatinib

N-(5-cloro-1,3-benzodioxol-4-il)-7-[2-(4-metilpiperazin-1-il)etoxi]-5-[(oxan-4-il)oxi]quinazolin-4-amina

C₂₇H₃₂ClN₅O₅**semagacestatum**

semagacestat


(2*S*)-2-hydroxy-3-methyl-*N*-[(2*S*)-1-[(1*S*)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1*H*-3-benzazépin-1-yl]amino]-1-oxopropan-2-yl]butanamide

sémagacestat

(2*S*)-2-hydroxy-3-méthyl-*N*-[(2*S*)-1-[(1*S*)-3-méthyl-2-oxo-2,3,4,5-tétrahydro-1*H*-3-benzazépin-1-yl]amino]-1-oxopropan-2-yl]butanamide

semagacestat

(2S)-2-hidroxi-3-metil-N-[(2S)-1-[[[(1S)-3-metil-2-oxo-2,3,4,5-tetrahidro-1H-3-benzazepin-1-il]amino]-1-oxopropan-2-il]butanamida

 $C_{19}H_{27}N_3O_4$


semuloparinum natricum
semuloparin sodium

sodium salt of a low molecular mass heparin that is obtained by phosphazene promoted depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 4-deoxy-2-O-sulfo- α -L-threo-hex-4-enopyranosuronic acid structure at the non-reducing end and a 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose structure at the reducing end of their chain; the molecular mass is defined by a repartition, no more than 40% is inferior to 1600 and no more than 11% is superior to 4500 Daltons, and by a mass-average value comprised between 2000 and 3000 Daltons; the degree of sulfatation is about 2.0 per disaccharidic unit

sémuloparine sodique

sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation à l'aide de phosphazène d'héparine de muqueuse intestinale de porc. La majorité des composants présente une structure acide 4-déoxy-2-O-sulfo- α -L-thréo-hex-4-énopyranosuronique à l'extrémité non réductrice et une structure 2-déoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative du produit est définie par une répartition, au plus 40% inférieur à 1600 et au plus 11% supérieur à 4500, et une moyenne comprise entre 2000 et 3000 ; le degré de sulfatation est voisin de 2 par unité disaccharide

semuloparina sódica

sal sódica de la heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización mediante un proceso controlado en el que se utiliza fosfazeno. La mayoría de los componentes presentan la estructura ácido 4-desoxi-2-O-sulfo- α -L-treo-hex-4-enopiranosurónico en el extremo no reductor y la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)-D-glucopiranososa en el extremo reductor de su cadena ; la masa molecular relativa del producto se define por una distribución, en la que, como máximo, un 40% es inferior a 1600 y, como máximo, un 11% es superior a 4500, y la media está comprendida entre 2000 y 3000 ; el grado de sulfatación es aproximadamente 2 por unidad de disacárido

sivifenum
sivifene


4,4'-[[2-(2,4-dinitrophenyl)hydrazinylidene]methylene]diphenol

sivifène

4,4'-[[2-(2,4-dinitrofényl)diazanylidène]méthylène]diphénol

sivifeno

4,4'-[[2-(2,4-dinitrofenil)hidrazinilideno]metileno]difenol

$C_{19}H_{14}N_4O_6$ **talarozolum**


talarozole

N-{4-[2-ethyl-1-(1*H*-1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine

talarozole

N-{4-[(1*R*)-2-ethyl-1-(1*H*-1,2,4-triazol-1-yl)butyl]phenyl}benzothiazol-2-amine

talarozol

N-{4-[2-etil-1-(1*H*-1,2,4-triazol-1-il)butil]fenil}-1,3-benzotiazol-2-amina $C_{21}H_{23}N_5S$ **talmapimodum**


talmapimod

2-[6-chloro-5-({(2*R*,5*S*)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl}carbonyl)-1-methyl-1*H*-indol-3-yl]-*N,N*-dimethyl-2-oxoacetamide

talmapimod

2-[6-chloro-5-({(2*R*,5*S*)-4-[(4-fluorophényl)méthyl]-2,5-diméthylpipérazin-1-yl}carbonyl)-1-méthyl-1*H*-indole-3-yl]-*N,N*-diméthyl-2-oxoacétamide

talmapimod

2-[6-cloro-5-({(2*R*,5*S*)-4-[(4-fluorofenil)metil]-2,5-dimetilpiperazin-1-il}carbonyl)-1-metil-1*H*-indol-3-il]-*N,N*-dimetil-2-oxoacetamida $C_{27}H_{30}ClFN_4O_3$ 

tanezumabum* tanezumab	immunoglobulin G2, anti-[<i>Homo sapiens</i> nerve growth factor beta (NGFB)], humanized monoclonal antibody, RN624; gamma2 heavy chain (1-447) [humanized VH (<i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR- <i>Homo sapiens</i> IGHJ4*01) [8.7.15] (1-121) - <i>Homo sapiens</i> IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (<i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR- <i>Homo sapiens</i> IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; (223-223":224-224":227-227":230-230")-tetradisulfide dimer <i>analgesic</i>
tanézumab	immunoglobuline G2, anti-[<i>Homo sapiens</i> facteur de croissance beta des nerfs (NGFB)], anticorps monoclonal humanisé, RN624; chaîne lourde gamma2 (1-447) [VH humanisé (<i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR- <i>Homo sapiens</i> IGHJ4*01) [8.7.15] (1-121) - <i>Homo sapiens</i> IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR- <i>Homo sapiens</i> IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dimère (223-223":224-224":227-227":230-230")-tetradisulfure <i>analgésique</i>
tanezumab	inmunoglobulina G2, anti-[<i>Homo sapiens</i> factor beta de crecimiento de los nervios (NGFB)], anticuerpo monoclonal humanizado, RN624; cadena pesada gamma2 (1-447) [VH humanizada (<i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR- <i>Homo sapiens</i> IGHJ4*01) [8.7.15] (1-121) - <i>Homo sapiens</i> IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (<i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR- <i>Homo sapiens</i> IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dímero (223-223":224-224":227-227":230-230")-tetradisulfuro <i>analgésico</i>
	$C_{6464}H_{9942}N_{1706}O_{2026}S_{46}$

tasimelteonum
tasimelteon

N-{[(1*R*,2*R*)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide


tasimeltéon

N-{[(1*R*,2*R*)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]méthyl}propanamide

tasimelteón

N-{[(1*R*,2*R*)-2-(2,3-dihidro-1-benzofuran-4-il)ciclopropil]metil}propanamida

$C_{15}H_{19}NO_2$



tasisulamum


tasisulam

N-(5-bromothiophene-2-sulfonyl)-2,4-dichlorobenzamide

tasisulam

N-[(5-bromothiophén-2-yl)sulfonyl]-2,4-dichlorobenzamide

tasisulam

N-(5-bromotiofeno-2-sulfonil)-2,4-diclorobenzamidaC₁₁H₆BrCl₂NO₃S₂**tasoglutidum**

tasoglutide

[8-(2-amino-2-methylpropanoic acid),35-(2-amino-2-methylpropanoic acid)]human glucagon-like peptide 1 (GLP-1)-(7-36)-peptidamide
 L-histidyl-2-methyl-L-alanyl-L-glutamylglycyl-L-threonyl-
 L-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L-valyl-L-seryl-L-seryl-
 L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminy-L-alanyl-L-lysyl-
 L-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-
 L-valyl-L-lysyl-2-methyl-L-alanyl-L-arginamide

tasoglutide


[8-(acide 2-amino-2-méthylpropanoïque),35-(acide 2-amino-2-méthylpropanoïque)]peptide 1 apparenté au glucagon humain
 (GLP-1)-(7-36)-peptidamide
 L-histidyl-2-méthyl-L-alanyl-L-glutamylglycyl-L-thréonyl-
 L-phénylalanyl-L-thréonyl-L-séryl-L-aspartyl-L-valyl-L-séryl-L-séryl-
 L-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminy-L-alanyl-L-lysyl-
 L-glutamyl-L-phénylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-
 L-valyl-L-lysyl-2-méthyl-L-alanyl-L-arginamide

tasoglutida

[8-(ácido 2-amino-2-metilpropanoico),35-(ácido 2-amino-2-metilpropanoico)]péptido 1 relacionado con el glucagón humano
 (7-36)-peptidamida
 L-histidil-2-metil-L-alanil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonil-
 L-seril-L-aspartil-L-valil-L-seril-L-seril-L-tirosil-L-leucil-L-glutamilglicil-
 L-glutaminil-L-alanil-L-lisil-L-glutamil-L-fenilalanil-L-isoleucil-L-alanil-
 triptofil-L-leucil-L-valil-L-lisil-2-metil-L-alanil-L-arginamida

C₁₅₂H₂₃₂N₄₀O₄₅

H—His—Aib—Glu—Gly—Thr—Phe—Thr—Ser—Asp—Val—Ser—Ser—
 7 10
 Tyr—Leu—Glu—Gly—Gln—Ala—Ala—Lys—Glu—Phe—Ile—Ala—
 20 30
 Trp—Leu—Val—Lys—Aib—Arg—NH₂



tecovirimatum

tecovirimat


N-[1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[*f*]isoindol-2(1*H*)-yl]-4-(trifluoromethyl)benzamide

técovirimat

N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-éthénocyclopropa[*f*]isoindol-2(1*H*)-yl)-4-(trifluorométhyl)benzamide

tecovirimat

N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahidro-4,6-etenociclopropa[*f*]isoindol-2(1*H*)-il)-4-(trifluorometil)benzamida

C₁₉H₁₅F₃N₂O₃**teneligliptinum**

teneligliptin


{{(2*S*,4*S*)-4-[4-(3-methyl-1-phenyl-1*H*-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone

ténéligliptine

{{(2*S*,4*S*)-4-[4-(3-méthyl-1-phényl-1*H*-pyrazol-5-yl)pipérazin-1-yl]pyrrolidin-2-yl}(thiazolidin-3-yl)méthanone

teneligliptina

{{(2*S*,4*S*)-4-[4-(1-fenil-3-metil-1*H*-pirazol-5-il)piperazin-1-il]pirrolidin-2-il}(1,3-tiazolidin-3-il)metanona

C₂₂H₃₀N₆OS**tildipirosinum**

tildipirosin


(4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-[2-(piperidin-1-yl)ethyl]-15-[(piperidin-1-yl)methyl]-2,10-dioxooxacyclohexadeca-11,13-dien-6-yl β-*D*-glucopyranoside

tildipirosine

(+)-(4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-6-[[3,6-didésoxy-3-(diméthylamino)-β-*D*-glucopyranosyl]oxy]-16-éthyl-4-hydroxy-5,9,13-triméthyl-7-[2-(pipéridin-1-yl)éthyl]-15-(pipéridin-1-ylméthyl)oxacyclohexadéca-11,13-diène-2,10-dione

tildipirosina

β-*D*-glucopiranosido de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-16-etil-4-hidroxi-5,9,13-trimetil-7-[2-(piperidin-1-il)etil]-15-[(piperidin-1-il)metil]-2,10-dioxooxaciclohexadeca-11,13-dien-6-ilo

C₄₁H₇₁N₃O₈**tosedostatum**


tosedostat

cyclopentyl (2*S*)-2-[(2*R*)-2-[(*S*)-hydroxy(hydroxycarbonyl)methyl]-4-methylpentanamido]-2-phenylacetate

tosédostat

(2*S*)-2-[(2*R*)-2-[(1*S*)-1-hydroxy-2-(hydroxyamino)-2-oxoéthyl]-4-méthylpentanoyle]amino)-2-phénylacétate de cyclopentyle

tosedostat

(2*S*)-2-[(2*R*)-2-[(*S*)-hidroxi(hidroxicarbamoil)metil]-4-metilpentanamido]-2-fenilacetato de ciclopentiloC₂₁H₃₀N₂O₆**troplasminogenum alfa #**

troplasminogen alfa

thrombin-activable plasminogen:
endo-[(558a(559)-558h(365))-human coagulation factor XI-(363-370)-peptide]-des-(559-562)-[606(610)-lysine,623(627)-lysine]human plasminogen, glycoform α

troplasminogène alfa

plasminogène activable par la thrombine :
endo-[(558a(559)-558h(365))-facteur XI de coagulation humain-(363-370)-peptide]-dès-(559-562)-[606(610)-lysine,623(627)-lysine]plasminogène humain, glycoforme α

troplasminógeno alfa

plasminógeno activable por la trombina :
endo-[(558a(559)-558h(365))-facteur XI de coagulación humano-(363-370)-péptido]-des-(559-562)-[606(610)-lisina,623(627)-lisina] plasminógeno humano, glicofoma α

C₃₈₇₅H₅₉₁₇N₁₁₀₇O₁₁₉₀S₅₈

EPLDDYVNTQ	GASLFSVTKK	QLGAGSIEEC	AAKCEEDEF	TCRAFQYHSK	50
EQQCVIMAEN	RKSSIIIRMR	DVLFEEKVY	LSECKTGNGK	NYRGTMSTK	100
NGITCQKWSS	TSPHRPRFSP	ATHPSEGLEE	NYCRNPDNDP	QGPWCYTDP	150
EKRYDYCDIL	ECCEECMHCS	GENYDGKISK	TMSGLECCQAW	DSQSPHAGHY	200
IPSKFPNKNL	KKNYCRNPDR	ELRPWCFTTD	PNKRWELCDI	PRCTTPPPSS	250
GPTYQCLKGT	GENYRGNVAV	TVSGHTCQHW	SAQTPHTHNR	TPENFPCKNL	300
DENYCRNPDG	KRAPWCHTTN	SQVRWEYCKI	FSCDSSPVST	EQLAPTAPPE	350
LTPVVQDCYH	GDDQSYRGTS	STTTTGKCCQ	SWSSMTPHRH	QKTPENYRNA	400
GLTMNYCRNP	DADKGPWCFT	TDPSVRWEYC	NLKKCSGTEA	SVVAPPPVVL	450
LPDVETPSEE	DCMFGNGKGY	RGKRATTVTG	TPCQDWAAQE	PHRHSIFTEPE	500
TNPRAGLEKN	YCRNPDGVDG	GPWCYTTPNR	KLYDYCDVPO	CAAPSFDCGK	550
PQVEPKKCTT	KIKPRIVGGC	VAHPHSWPWQ	VSLRTRFGMH	FCGGTLISPE	600
WVLTAAHCLK	KSPRPSSYKV	ILGAHQKVNIL	EPHVQEIFVS	RLFLEPTRKD	650
IALLKLSSPA	VITDKVIPAC	LSPSNYVVAD	RTECFITGNG	ETQGTFGAGL	700
LKEAQLPVIE	NKVCNRYEFL	NGRVQSTELC	AGHLAGGTDS	CQGDSSGGPLV	750
CFEKDKYILQ	GVTSWGCGCA	RPNKPGVYVR	VSRFVTWIEG	VMRNN	795

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 30-54 34-42 84-162 105-145 133-157 166-243 169-297 187-226
 215-238 256-333 277-316 305-328 358-435 379-418 407-430 462-541
 483-524 512-536 548-670 558-570 592-608 684-751 714-730 741-769

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
 Ser-249 Asn-289 Thr-346

ustekinumab #

ustekinumab

immunoglobulin G1, anti-[*Homo sapiens* interleukin 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF p40)], *Homo sapiens* monoclonal antibody, CNTO 1275; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

ustékinumab

immunoglobulin G1, anti-[*Homo sapiens* interleukine 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF2 p40)], *Homo sapiens* anticorps monoclonal, CNTO 1275; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

ustekinumab

inmunoglobulina G1, anti-[*Homo sapiens* interleukina 12B (IL12B, IL12 p40, factor 2 estimulante de las células *natural killer* NKSF2, factor 2 citotóxico de la maduración de linfocitos, CLMF2, CMLF2 p40)], *Homo sapiens* anticuerpo monoclonal, CNTO 1275; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

C₆₄₈₂H₁₀₀₀₄N₁₇₁₂O₂₀₁₆S₄₆**vadimezanum**

vadimezan


2-(6,7-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid

vadimézan

acide (5,6-diméthyl-9-oxo-9H-xanthén-4-yl)acétique

vadimezan

ácido 2-(6,7-dimetil-9-oxo-9H-xanten-4-ilo)acético

$C_{17}H_{14}O_4$ **velneperitum**


velneperit

(1*r*,4*s*)-4-(1,1-dimethylethanesulfonamido)-*N*-[5-(trifluoromethyl)pyridin-2-yl]cyclohexanecarboxamide

velnépérit

(1*r*,4*s*)-4-(1,1-diméthyléthanesulfonamido)-*N*-[5-(trifluorométhyl)pyridin-2-yl]cyclohexanecarboxamide

velneperit

(1*r*,4*s*)-4-(1,1-dimetiletanosulfonamido)-*N*-[5-(trifluorometil)piridin-2-il]ciclohexanocarboxamida $C_{17}H_{24}F_3N_3O_3S$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales recommandées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

p. 7	<i>delete</i> cipamfylline	<i>replace</i> cipamfyllinum
------	-------------------------------	---------------------------------

Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

p. 256	<i>delete</i> netupitant	<i>replace</i> netupitantum
--------	-----------------------------	--------------------------------

Recommended International Nonproprietary Names (Rec. INN): List 57
Dénominations communes internationales recommandées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 55	aclidinii bromidum aclidinium bromide	<i>replace the chemical name by the following</i> (3 <i>R</i>)-3-[[hydroxydi(thiophen-2-yl)acetyl]oxy]-1-(3-phenoxypropyl)- 1λ ⁵ -azabicyclo[2.2.2]octan-1-ylum bromide
	bromure d'aclidinium	<i>remplacer le nom chimique par le suivant</i> bromure de (3 <i>R</i>)-3-[[hydroxydi(thiophén-2-yl)acétyl]oxy]-1-(3-phénoxypropyl)- 1λ ⁵ -azabicyclo[2.2.2]octan-1-ylum

Recommended International Nonproprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)

p. 264	aclidinii bromidum bromuro de aclidinio	<i>sustitúyase el nombre químico por el siguiente</i> bromuro de (3 <i>R</i>)-1-(3-fenoxipropil)-3-[[hidroxidi(tiofen-2-yl)acetil]oxi]- 1λ ⁵ -azabicyclo[2.2.2]octan-1-ilio
--------	---	---

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 63 *delete* *replace*
 rabeximod rabeximodum

Recommended International Non Proprietary Names (Rec. INN): List 60
Dénominations communes internationales recommandées (DCI Rec.): Liste 60
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 60
(WHO Drug Information, Vol. 22, No. 3, 2008)

p. 232 *delete* *replace*
 eribaxaban eribaxabanum

- # Electronic structure available on Mednet: <http://mednet.who.int/>
Structure électronique disponible sur Mednet: <http://mednet.who.int/>
Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.